Asia-Pacific Ophthalmic Therapeutics/Drug Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Ophthalmic Therapeutics/Drug Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Antiallergy Market Performance (Volume)
  • 2.1.2 Anti-VEGF agents Market Performance (Volume)
  • 2.1.3 Anti-inflammatory Market Performance (Volume)
  • 2.1.4 Antiglaucoma Market Performance (Volume)
  • 2.1.5 Others Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Antiallergy Market Performance (Value)
  • 2.1.2 Anti-VEGF agents Market Performance (Value)
  • 2.1.3 Anti-inflammatory Market Performance (Value)
  • 2.1.4 Antiglaucoma Market Performance (Value)
  • 2.1.5 Others Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Dry Eye Market Performance (Volume)
  • 3.1.2 Allergies Market Performance (Volume)
  • 3.1.3 Glaucoma Market Performance (Volume)
  • 3.1.4 Inflammation/Infection Market Performance (Volume)
  • 3.1.5 Retinal Disorders Market Performance (Volume)
  • 3.1.6 Uveitis Market Performance (Volume)
  • 3.1.7 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Novartis AG
  • 4.1.1 Novartis AG Profiles
  • 4.1.2 Novartis AG Product Information
  • 4.1.3 Novartis AG Ophthalmic Therapeutics/Drug Business Performance
  • 4.1.4 Novartis AG Ophthalmic Therapeutics/Drug Business Development and Market Status
• 4.2 Allergan
  • 4.2.1 Allergan Profiles
  • 4.2.2 Allergan Product Information
  • 4.2.3 Allergan Ophthalmic Therapeutics/Drug Business Performance
  • 4.2.4 Allergan Ophthalmic Therapeutics/Drug Business Development and Market Status
• 4.3 Santen Pharmaceutical Co., Ltd.
  • 4.3.1 Santen Pharmaceutical Co., Ltd. Profiles
  • 4.3.2 Santen Pharmaceutical Co., Ltd. Product Information
  • 4.3.3 Santen Pharmaceutical Co., Ltd. Ophthalmic Therapeutics/Drug Business Performance
  • 4.3.4 Santen Pharmaceutical Co., Ltd. Ophthalmic Therapeutics/Drug Business Development and Market Status
• 4.4 Pfizer Inc.
  • 4.4.1 Pfizer Inc. Profiles
  • 4.4.2 Pfizer Inc. Product Information
  • 4.4.3 Pfizer Inc. Ophthalmic Therapeutics/Drug Business Performance
  • 4.4.4 Pfizer Inc. Ophthalmic Therapeutics/Drug Business Development and Market Status
• 4.5 Merck & Co., Inc.
  • 4.5.1 Merck & Co., Inc. Profiles
  • 4.5.2 Merck & Co., Inc. Product Information
  • 4.5.3 Merck & Co., Inc. Ophthalmic Therapeutics/Drug Business Performance
  • 4.5.4 Merck & Co., Inc. Ophthalmic Therapeutics/Drug Business Development and Market Status
• 4.6 Genentech, Inc.
  • 4.6.1 Genentech, Inc. Profiles
  • 4.6.2 Genentech, Inc. Product Information
  • 4.6.3 Genentech, Inc. Ophthalmic Therapeutics/Drug Business Performance
  • 4.6.4 Genentech, Inc. Ophthalmic Therapeutics/Drug Business Development and Market Status

5 Market Performance for Manufacturers

• 5.1 Asia-Pacific Ophthalmic Therapeutics/Drug Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Asia-Pacific Ophthalmic Therapeutics/Drug Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Asia-Pacific Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Asia-Pacific Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 Japan Market Performance for Manufacturers
  • 6.2.1 Japan Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 Japan Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 Japan Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 Japan Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 South Korea Market Performance for Manufacturers
  • 6.3.1 South Korea Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 South Korea Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 South Korea Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 South Korea Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Taiwan Market Performance for Manufacturers
  • 6.4.1 Taiwan Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Taiwan Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Taiwan Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Taiwan Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 India Market Performance for Manufacturers
  • 6.5.1 India Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 India Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 India Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 India Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Southeast Asia Market Performance for Manufacturers
  • 6.6.1 Southeast Asia Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Southeast Asia Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Southeast Asia Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Southeast Asia Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Australia Market Performance for Manufacturers
  • 6.7.1 Australia Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Australia Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Australia Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Australia Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Ophthalmic Therapeutics/Drug Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Ophthalmic Therapeutics/Drug Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Ophthalmic Therapeutics/Drug Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Ophthalmic Therapeutics/Drug Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Asia-Pacific Ophthalmic Therapeutics/Drug Market Performance (Sales Point)

• 7.1 Asia-Pacific Ophthalmic Therapeutics/Drug Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Asia-Pacific Ophthalmic Therapeutics/Drug Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Asia-Pacific Ophthalmic Therapeutics/Drug Price (USD/Unit) by Regions 2013-2018
• 7.4 Asia-Pacific Ophthalmic Therapeutics/Drug Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Asia-Pacific Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 Japan Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 South Korea Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Taiwan Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 India Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Southeast Asia Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Australia Ophthalmic Therapeutics/Drug Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Dry Eye Industry
• 11.2 Allergies Industry
• 11.3 Glaucoma Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Asia-Pacific Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Asia-Pacific Ophthalmic Therapeutics/Drug Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 China Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 Japan Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 South Korea Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Taiwan Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 India Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Southeast Asia Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Australia Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.10 Ophthalmic Therapeutics/Drug Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Antiallergy Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Anti-VEGF agents Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Anti-inflammatory Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Antiglaucoma Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Dry Eye Sales and and Growth Rate 2019-2024
  • 12.4.3 Allergies Sales and and Growth Rate 2019-2024
  • 12.4.4 Glaucoma Sales and and Growth Rate 2019-2024
  • 12.4.5 Inflammation/Infection Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Asia-Pacific Ophthalmic Therapeutics/Drug Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Asia-Pacific Ophthalmic Therapeutics/Drug Gross Profit Trend 2019-2024

13 Conclusion